MDAngle

• A Golden Era of Atopic Dermatitis: New Therapies Address Unmet Needs   Jonathan Silverberg, MD, PhD, MPH, discusses exciting new oral, injectable, and topical therapies that have the potential to significantly alter the treatment landscape for atopic dermatitis.
  Medscape, June 29, 2022
• Management of Atopic Dermatitis: Bringing Therapy Into Focus   Saakshi Khattri, MD, recounts the evolution of treatments for atopic dermatitis (AD), from the widespread use of general immune suppressants such as methotrexate and cyclosporine, to more recent, targeted agents.
  Medscape, June 29, 2022
• ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer   Tracy L. Rose, MD, MPH, discusses the immediate impact that study data from the 2022 ASCO annual meeting bladder cancer poster sessions will have on treatment decisions facing providers and patients.
  Medscape, June 27, 2022
• ASCO 2022: Encouraging Data for Patient Subgroups in the Treatment of Melanoma   Michael A. Postow, MD, considers the practical applications of data presented at ASCO 2022, with an emphasis on the potential impact on certain patient subgroups.
  Medscape, June 24, 2022
• A Mentor Who Helped Me Find Options for Patients With Atopic Dermatitis   Jonathan Silverberg, MD, PhD, MPH, highlights a mentor who helped shape his philosophy and approach to challenging cases of atopic dermatitis.
  Medscape, June 24, 2022
• Knowledge Gaps and Disparities in the Treatment of Atopic Dermatitis   Jonathan Silverberg, MD, PhD, MPH, recalls a patient whose severe atopic dermatitis was overlooked due to systemic bias.
  Medscape, June 24, 2022
• ASCO 2022: Immediate Options for Endocrine Therapy-Refractory Patients With HER2-Low Metastatic Breast Cancer   Tarah J. Ballinger, MD, discusses the implications of the DESTINY-Breast 04 trial and the immediate impact that it will have on the lives of her patients.
  Medscape, June 23, 2022
• The Impact of Racial Disparities in the Diagnosis and Treatment of Atopic Dermatitis   Jonathan Silverberg, MD, PhD, MPH, discusses the importance of considering racial disparities in the diagnosis and treatment of atopic dermatitis.
  Medscape, June 23, 2022
• ASCO 2022: A New Era in the Treatment of Metastatic Breast Cancer   Avan J. Armaghani, MD, provides a postconference perspective on data shared at ASCO 2022, including the cumulative effect of the latest results from the DESTINY-Breast04.
  Medscape, June 22, 2022
• ASCO 2022: An Abundance of Data for the Field of Melanoma   Michael Postow, MD, offers an immediate reflection on data presented at the ASCO 2022 conference.
  Medscape, June 22, 2022
• Management of Atopic Dermatitis: Addressing the Deficits   "To be able to effectively diagnose atopic dermatitis in skin of color, to be able to diagnose it early on, and to be able to effectively treat them is a huge unmet need in the atopic dermatitis space," says Saakshi Khattri, MD.
  Medscape, June 22, 2022
• Management of Atopic Dermatitis: Therapeutic Advances   Saakshi Khattri, MD, describes a state of unceasing misery for a young patient who, while coping with the exacting symptoms of a nearly lifelong case of atopic dermatitis (AD), was treated with the monoclonal antibody dupilumab.
  Medscape, June 21, 2022
• ASCO 2022: New Treatments and Novel Therapies in Advanced Bladder Cancer   Cheryl Lee, MD, shares her impressions on results presented at ASCO 2022 including outcomes from QUILT-3.032, SWOG S1314, COSMIC-021, and LEAP-011.
  Medscape, June 20, 2022
• ASCO 2022: A Trio of Promising Treatments for Bladder Cancer   Tracy Rose, MD, reviews the QUILT 3.032, SAKK 06/17, and poster discussions on recent bladder cancer research from ASCO 2022.
  Medscape, June 14, 2022
• ASCO 2022: Cutting-Edge Performances by Antibody-Drug Conjugates in the Treatment of Breast Cancer   Avan Armaghani, MD, discusses findings from the TROPiCS-02 and DESTINY-Breast04 trials.
  Medscape, June 14, 2022
• ASCO 2022: Redefining the Treatment Landscape in Metastatic Breast Cancer   Tarah J. Ballinger, MD, discusses key findings from the DESTINY-04, PALOMA-2, MAINTAIN, and TROPiCS-2 studies that were presented at ASCO 2022.
  Medscape, June 10, 2022
• ASCO 2022: Fresh Data in the Setting of Metastatic Breast Cancer Treatment   Avan J. Armaghani, MD, reviews the research on metastatic breast cancer to be presented at this year's ASCO conference.
  Medscape, June 03, 2022
• Approaching ASCO 2022: Collaborations in the Management of Bladder Cancer   Cheryl Lee, MD, highlights sessions at ASCO 2022 on applications of AI and radiology, advances in molecular therapies, and challenging case studies in the management of bladder cancer.
  Medscape, May 26, 2022
• Approaching ASCO 2022: Reaching New Plateaus in the Treatment of Melanoma   Jeffrey S. Weber, MD, PhD, discusses the follow-ups on previously published studies that he anticipates hearing during the upcoming ASCO conference.
  Medscape, May 26, 2022
• ASCO 2022: Advancing Therapies in Metastatic Breast Cancer   Tarah J. Ballinger, MD, expects reinvigoration and positive results this year at the 2022 ASCO Annual Meeting and to bring more care options back to her patients with metastatic breast cancer.
  Medscape, May 26, 2022